Abstract：【Objective】To investigate the clinical efficacy of robot assisted partial nephrectomy in the treatment of solitary renal tumors. 【Methods】 The clinical data of 12 patients with solitary renal tumors treated by robot assisted partial nephrectomy in our hospital from June 2016 to January 2018 were retrospectively analyzed, including 1 case of contralateral renal atrophy, 2 cases of congenital solitary kidney, 1 case of contralateral benign renal disease and 8 cases of contralateral malignant renal tumor. All patients underwent robot assisted partial nephrectomy. The operation conditions were recorded and followed up for 12 months. The incidence of postoperative complications and prognosis were recorded. 【Results】The operation of 12 patients was successfully completed, and there was no conversion to open operation. The operation time was 108~210 min, with an average of(163.5 ± 15.4) min; The intraoperative bleeding volume was 120~460 mL, with an average of(240.6 ± 25.7) mL; The hospital stay was 6~15 days, with an average of(9.8 ± 2.1) days. Postoperative pathological diagnosis:9 cases of renal clear cell carcinoma and 3 case of angioleiomyoma, the cutting edge was negative, and the tumor capsule was relatively complete. One patient developed hematuria and one patient developed infection. All patients returned to normal after relevant effective intervention. Following up for 3 months, 12 patients had normal renal function indexes such as serum creatinine, urea nitrogen, glomerular filtration rate and urinary albumin; Followed up for 6 months, 1 patient had a slight increase in serum creatinine and urea nitrogen; After 9 months of follow-up, 2 patients had significantly increased serum creatinine and urea nitrogen, and the qualitative examination of proteinuria was positive; After 12 months of follow-up, the glomerular filtration rate of 1 patient was less than 100 ml/min, but no patient underwent renal dialysis, and there was no tumor recurrence and metastasis. 【Conclusion】Robot assisted partial nephrectomy can effectively preserve the renal function of patients with solitary renal tumor, has high safety, and is worthy of popularization and application.
2021, Vol. 38 
